IMP321
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for IMP321, covering 2008-04-24 to 2021-10-05. Get the full timeline:
Most recent: Clinical Trial Update: IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma [Phase 2]